期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雌激素受体α共激活子与乳腺癌 被引量：1

Estrogen receptor α coactivator and breast cancer
下载PDF
导出
摘要 在乳腺癌发生发展过程中,雌激素受体(estrogen receptor α,ERα)信号途径的活性增强,一个重要的原因是ERα共调节因子的变化。ERα共调节因子可分为共激活子和共抑制子。本文对ERα共激活子的种类、与ERα的结合方式、作用机制及其与乳腺癌的关系进行了综述。 During the development of breast cancer, the activity of estrogen receptor α （ERα）signaling pathway can be enhanced. One of the important reason is the change of ERα coregulors. The coregulators can be divided into coactivators and corepressors. The present review iocuses on the Ella coac-tivator in combining with ERα, with a specific emphasis on the ERα activator activities in breast cancer.
作者 钟雅琴 钟警 文格波
机构地区 南华大学附属第一医院临床研究所 南华大学附属第一医院内分泌科
出处 《国际病理科学与临床杂志》 CAS 2009年第4期298-302,共5页 Journal of International Pathology and Clinical Medicine
基金 国家自然科学基金(30670993)~~
关键词 雌激素受体 共激活子 乳腺癌 estrogen receptor coactivator breast cancer
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Mangelsdoff D J, Thummel C, Beato M, et al. The nuclear receptor superfamily : the second decade [ J ]. Cell, 1995,83 (6) :835-839.
  • 2Klinge CM. Estrogen receptor interaction with co-activators and corepressors [ J ]. Steroids, 2000,65 ( 5 ) :227 -251.
  • 3Aranda A, Pascual A. Nuclear hormone receptors and gene expression [ J ]. Physiol Rev,2001,81 ( 3 ) : 1269 -1304.
  • 4Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action : from concept to therapeutic targeting[ J ]. Mol Interv ,2005, 5 (6) :343-357.
  • 5Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers[ J]. Br J Cancer,2007,96( 1 ) : 11-15.
  • 6Feng W, Ribeiro RC, Wagner RL, et al. Hormone dependent coactivator binding to a hydrophobic cleft on nuclear receptors [ J ]. Science,1998,280(5370) :1747-1749.
  • 7Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen [ J ]. Cell, 1998,95 ( 7 ) :927 -937.
  • 8Heery DM,Kalkhoven E,Hoare S,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors [ J ]. Nature, 1997,387 (6634) :733-736.
  • 9Kishimoto H, Wang Z, Bhat-Nakshatri P, et al. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1 /CXCL12 [ J ]. Cinogenesis,2005,26(10) :1706-1715.
  • 10Wang S, Yuan YH, Liao L, et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation[ J ]. PNAS,2009,106( 1 ) : 151-156.

同被引文献21

  • 1Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes current opinion in endocrinology[J]. Curr Opin Endocrinol Diabetes Obes, 2011, 18 (1):75-82.
  • 2Evers BM. Neurotensin and growth of normal and neoplastic tissues[J]. Peptides, 2006, 27(10):2424-2433.
  • 3Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools[J]. Peptides, 2006, 27(10):2445-2460.
  • 4Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors[J]. Bioconjug Chem, 2011, 22(7):1374-1385.
  • 5Zhang K, An R, Gao Z, et al. Radionuclide imaging of small- cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13[J]. Nucl Med Biol, 2006, 33(4):505-512.
  • 6Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells[J]. Mol Cancer Res, 2009, 7(5):724-734.
  • 7Myers RM, Shearman JW, Kitching MO, et al. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors[J]. ACS Chem Biol, 2009, 4(7):503- 525.
  • 8Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers[J]. Biochimie, 2011, 93(9):1369-1378.
  • 9Wang JG, Li NN, Li HN, et al. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-I and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1 [J]. Neuropeptides, 2011, 45(2):151-156.
  • 10Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? [J]. Cell Signal, 2001, 13(1):1-6.

引证文献1

二级引证文献1

国际病理科学与临床杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部